Clinical Trials Logo

Clinical Trial Summary

This is a phase 2, multicenter, randomized, double-blind, parallel group, 2 arm study in approximately 40 subjects aged 4 to 50 years, inclusive, who are allergic to cow's milk. The primary objective is to assess whether dupilumab as an adjunct to milk oral immunotherapy (OIT) compared to placebo improves the safety of milk OIT and rates of desensitization, defined as an increase in the proportion of subjects who pass a double-blind placebo-controlled food challenge (DBPCFC) to at least 2040 mg cumulative milk protein at week 18.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04148352
Study type Interventional
Source Stanford University
Contact Andrew Long, PharmD
Phone 650-521-7237
Email snpcenterallergy_scheduler@stanford.edu
Status Recruiting
Phase Phase 2
Start date October 18, 2021
Completion date November 2026